PALI Stock Summary and Trading Ideas (Palisade Bio | NASDAQ:PALI)

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Palisade Bio trades on the NASDAQ stock market under the symbol PALI.

As of September 1, 2026, PALI stock price climbed to $1.96 with 853,944 million shares trading.

PALI has a beta of 0.34, meaning it tends to be less sensitive to market movements. PALI has a correlation of 0.00 to the broad based SPY ETF.

PALI has a market cap of $341.57 million. This is considered a Small Cap stock.

In the last 3 years, PALI traded as high as $28.95 and as low as $.53.

The top ETF exchange traded funds that PALI belongs to (by Net Assets): IWM, VXF, IWN, VTWO, IWC.

PALI has outperformed the market in the last year with a return of +190.0%, while the SPY ETF gained +19.3%. However, in the most recent history, PALI shares have underperformed the stock market with its stock returning -7.5% in the last 3 month period and -8.8% for the last 2 week period, while SPY has returned +1.0% and -1.4%, respectively.

PALI support price is $1.87 and resistance is $2.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PALI shares will trade within this expected range on the day.